100% accuracy
of data
of data
24/7 scientific
support
support
0% tolerance in
quality of product
quality of product
Stock Locations
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* Stock subject to availability.
Documentation
Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.
849206-43-5Olmesartan EP Impurity B
● In Stock
| Catalogue No.: | VL184001 |
|---|---|
| CAS No.: | 849206-43-5 |
| Mol. Formula: | C24H24N6O2 |
| Mol. Weight: | 428.49 g/mol |
Additional information on CAS 849206-43-5
Parent drug
OlmesartanIUPAC Name
6,6-dimethyl-2-propyl-3-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-3,6-dihydro-4H-furo[3,4-d]imidazol-4-oneSynonyms
Olmesartan Related Compound A; Olmesartan EP Impurity B; Olmesartan Gama-Lactone; Olmesartan Lactone; Olmesartan Lactone Impurity; 3, 6-Dihydro-6, 6-dimethyl-2-propyl-3-[[2′-(2H-tetrazol-5-yl)[1, 1′-biphenyl]-4-yl]methyl]-4H-Furo[3, 4-d]imidazol-4-one; Olmesartan EP Impurity B;Description
Olmesartan EP Impurity B (CAS No: 849206-43-5) or Olmesartan Lactone Impurity is an impurity present in olmesartan which is an angiotensin II receptor blocker that selectively blocks the binding of angiotensin 2 to the AT1 receptor in vascular smooth muscle.References
Srinivasu, Kondra, et al. “Novel Analytical Method Using Acquity QDa Mass Detector Coupled with LC-PDA for Impurity Profiling of Amlodipine Besylate and Olmesartan Medoxomil in Fixed Dose Tablets Formulation.†Saudi Journal of Medical and Pharmaceutical Sciences, vol. 05, no. 10, Oct. 2019, pp. 871–84, https://doi.org/10.36348/sjmps.2019.v05i10.008.?Request a Quote
"*" indicates required fields
Other products related to Olmesartan impurities
Impurity structure
Parent Drug Name
CAS No.
Name of Impurity
Catalog No.
Olmesartan / Losartan / Candesartan/ Irbesartan / Zidovudine
CAS No. 76-84-6
Cat No. VL184004
